Following Pre-NDA Meeting With The FDA, UroGen Announces Rolling NDA Submission For UGN-102 For Low-grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer To Begin January 2024
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma has announced that it will begin the rolling NDA submission for UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, in January 2024. This follows a pre-NDA meeting with the FDA.
October 03, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen's announcement of the rolling NDA submission for UGN-102 in January 2024 could potentially impact the company's stock positively as it indicates progress in the drug's development.
The announcement of the rolling NDA submission for UGN-102 indicates progress in the drug's development and regulatory approval process. This could potentially lead to increased investor confidence in UroGen, positively impacting the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100